BridgeBio is substantially boosted the course of a new solution for ATTR-CM, leveraging the compound. Preliminary trial results suggests promising outcomes for those affected with this debilitating illness. This effort https://biotech068531.blog-a-story.com/24019716/firm-progresses-cardiac-amyloidosis-therapy-through-the-therapy